Refractory Solid Tumors clinical trials

Explore recruiting refractory solid tumors clinical trials.

Recruiting refractory solid tumors studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Refractory Solid Tumors trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

First-in-human interleukin-15-transpresenting Wilms’ tumor protein 1-targeting autologous dendritic cell vaccination in cancer patients

Belgium

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A5481092: PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS

Sweden, France, Czechia, Slovakia, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants with Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors

Spain, France, Germany, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

I3Y-MC-JPCS: A Phase 1b/2 Study of Abemaciclib in Combination with Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination with Temozolomide (Part B) in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors and Abemaciclib in Combination with Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients with Relapsed/Refractory Neuroblastoma (Part C).

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase I, Open-label, Multi-center, First-in-human Trial to Investigate E303, in Participants with Advanced Refractory Solid Tumors

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-21822 Monotherapy and Combination Therapy in Adult Patients with Advanced Solid Tumors Harboring KRAS G12C Mutation

Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Refractory Solid Tumors trials by city

Refractory Solid Tumors in Toronto Refractory Solid Tumors in Vancouver Refractory Solid Tumors in Montreal Refractory Solid Tumors in Calgary Refractory Solid Tumors in Edmonton Refractory Solid Tumors in Ottawa Refractory Solid Tumors in Winnipeg Refractory Solid Tumors in Quebec City Refractory Solid Tumors in Hamilton Refractory Solid Tumors in Kitchener Refractory Solid Tumors in London Refractory Solid Tumors in Halifax Refractory Solid Tumors in New York Refractory Solid Tumors in Los Angeles Refractory Solid Tumors in Chicago Refractory Solid Tumors in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease